Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Investigation Of The Genetic Disparities Between African Americans and Causasians Utilizing Gene Expression Profiles (GEP) Of Purified Plasma Cells (PC) and Whole Bone Marrow Biopsies (BMBx)

Adam Rosenthal, Christoph Heuck, MD, Aziz Bakhous, M.D., Frits van Rhee, MD, PhD, Antje Hoering, PhD, Sarah Waheed, MD, Nathan M Petty, MS, Clyde Bailey, Donald Johann, MD, MS, Joshua Epstein, DSc, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2013) 122 (21): 1870.

https://doi.org/10.1182/blood.V122.21.1870.1870

Published: 2013

Journal Articles

Final Results Of Phase II Study Of Pomalidomide (Pom) In GEP-Defined High Risk Relapsed and Refractory Multiple Myeloma (RRMM)

Saad Z Usmani, MD, FACP, Kelly Stratton, Emily Hansen, MS, Qing Zhang, PhD, Susan B. Panozzo, BS, Nathan M Petty, MS, Antje Hoering, Sarah Waheed, MD, Frits van Rhee, John Crowley, PhD, Bart Barlogie, MD

Blood (2013) 122 (21): 3191.

https://doi.org/10.1182/blood.V122.21.3191.3191

Published: 2013

Journal Articles

Impact Of Elotuzumab Therapy On Circulating and Ex Vivo Activated/Expanded Autologous Natural Killer (Auto-ENK) Cell Activity

Susann Szmania, BS, Amy D Greenway, BS, Joshuah D Lingo, BS, Katie Stone, BS, Junaid Khan, PhD, Tarun K. Garg, PhD, Nathan M Petty, MS, Susan B. Panozzo, BS, Emily Woods, BS, Jessica Warden, Joshua Epstein, DSc, Bart Barlogie, MD, PhD, Frits van Rhee, MD,PhD

Blood (2013) 122 (21): 5389.

https://doi.org/10.1182/blood.V122.21.5389.5389

Published: 2013

Journal Articles

Role Of Cytogenetic Abnormalities At Baseline and During 5-Year Follow-Up In Multiple Myeloma Patients Treated On The Total Therapy 3 Protocol

Sarah Waheed, MD, Jeffrey Sawyer, PhD, Adam Rosenthal, Frits van Rhee, MD, PhD, Nathan M Petty, MS, Saad Z Usmani, MD, FACP, Clyde Bailey, Christoph Heuck, MD, Antje Hoering, PhD, Bart Barlogie, MD, PhD

Blood (2013) 122 (21): 3137.

https://doi.org/10.1182/blood.V122.21.3137.3137

Published: 2013

Journal Articles

Total Therapy (TT) Studies For Gene Expression Profiling (GEP)-Defined High-Risk Multiple Myeloma

Christoph Heuck, MD, Frits van Rhee, MD, PhD, Alan Mitchell, Adam Rosenthal, Sarah Waheed, MD, Nathan M Petty, MS, Clyde Bailey, Ryan Williams, Ryan van Laar, PhD, Susan B. Panozzo, BS, Jeffrey Sawyer, PhD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2013) 122 (21): 126.

https://doi.org/10.1182/blood.V122.21.126.126

Published: 2013

Journal Articles

Secondary Myelodysplasia-Associated Metaphase Cytogenetic Abnormalities in Newly Diagnosed Multiple Myeloma Treated On Total Therapies 2 & 3– Influence of Cumulative Dosing of Maintenance Drugs

Saad Z Usmani, MD FACP, Adam Rosenthal, Rachael Sexton, Antje Hoering, Zeba N Singh, MD, Sarah Waheed, MD, Al-Ola Abdallah, MD, Jameel Muzaffar, MD, Nathan M Petty, John Crowley, PhD, Jeffrey Sawyer, PhD, Joshua Epstein, DSc, Frits van Rhee, MD, PhD, Bart Barlogie, MD, PhD

Blood (2012) 120 (21): 324.

https://doi.org/10.1182/blood.V120.21.324.324

Published: 2012

Journal Articles

Identifying the Outliers Among Gene Expression Profiling (GEP)-Defined Low-Risk Myeloma Patients Treated with Total Therapy 2 and 3 (TT2, TT3)

Frits van Rhee, MD, PhD, Sarah Waheed, MD, Saad Z Usmani, MD FACP, Joshua Epstein, DSc, Adam Rosenthal, Christoph Heuck, MD, Jameel Muzaffar, MD, Al-Ola Abdallah, MD, Nathan M Petty, Clyde Bailey, Antje Hoering, Bart Barlogie, MD, PhD

Blood (2012) 120 (21): 195.

https://doi.org/10.1182/blood.V120.21.195.195

Published: 2012

Journal Articles

Abnormal Hevylite Assay Ratio As a Prognostic Marker for Survival in Newly Diagnosed Multiple Myeloma Patients Treated On Total Therapy 3

Josh Bornhorst, Adam Rosenthal, Rachael Sexton, Alan Mitchell, Linda Traylor, PhD, Antje Hoering, PhD, Frits van Rhee, MD, PhD, John Crowley, PhD, Nathan M Petty, Stephen Harding, PhD, Bart Barlogie, MD, PhD, Saad Z Usmani, MD FACP

Blood (2012) 120 (21): 3976.

https://doi.org/10.1182/blood.V120.21.3976.3976

Published: 2012

Journal Articles

Phase II Study of Pomalidomide (Pom) in Genomically Defined High Risk Relapsed and Refractory Multiple Myeloma (RRMM)

Saad Z Usmani, MD, FACP, Emily Hansen, MS, Doug Steward, Sarah Waheed, MD, Susan B. Panozzo, Nathan M Petty, Shebli Atrash, MD, Al-Ola Abdallah, MD, Nisar Ahmad, MD, Antje Hoering, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2012) 120 (21): 4083.

https://doi.org/10.1182/blood.V120.21.4083.4083

Published: 2012

Journal Articles

18-FDG PET Focal Lesion and Avidity Suppression As Early As Day-7 Post-Induction Chemotherapy Predicts for Superior Outcome in Newly Diagnosed Multiple Myeloma Patients Treated with Total Therapy 3 Trials.

Saad Z Usmani, MD FACP, Sarah Waheed, MD, Alan Mitchell, John Crowley, PhD, Antje Hoering, Nathan M Petty, Joshua Epstein, DSc, Christoph Heuck, MD, Shmuel Yaccoby, PhD, Donald Johann, MD, MS, Frits van Rhee, MD, PhD, Bart Barlogie, MD, Ph.D

Blood (2012) 120 (21): 2910.

https://doi.org/10.1182/blood.V120.21.2910.2910

Published: 2012

Journal Articles

Total Therapy 6: Initial Results of Dose-Dense Strategy for Previously Treated Multiple Myeloma

Saad Usmani, MD, FACP, Alan Mitchell, Bijay Nair, MD, Sarah Waheed, MD, Frits van Rhee, MD, PhD, Yazan Alsayed, MD, Nathan M Petty, Doug Steward, Susan Panozzo, Antje Hoering, PhD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2011) 118 (21): 3081.

https://doi.org/10.1182/blood.V118.21.3081.3081

Published: 2011

Journal Articles

Pomalidomide (Pom) in Relapsed and Refractory Multiple Myeloma (RRMM) - theUARK Compassionate Use Protocol,

Saad Usmani, MD, FACP, Sarah Waheed, MD, Jackie Szymonifka, Susan Panozzo, Nathan M Petty, Doug Steward, Bijay Nair, MD, Yazan Alsayed, MD, Antje Hoering, PhD, John Crowley, PhD, Bart Barlogie, MD, Ph.D

Blood (2011) 118 (21): 3995.

https://doi.org/10.1182/blood.V118.21.3995.3995

Published: 2011

Journal Articles

Second Malignancies in Total Therapy 3 Trials for Newly Diagnosed Multiple Myeloma: Influence of Lenalidomide Versus Thalidomide in Maintenance Phases

Saad Usmani, MD, FACP, Rachael Sexton, Antje Hoering, PhD, Christoph Heuck, MD, Bijay Nair, MD, Sarah Waheed, MD, Yazan Alsayed, MD, Nathan M Petty, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2011) 118 (21): 823.

https://doi.org/10.1182/blood.V118.21.823.823

Published: 2011

NARROW

Investigation Of The Genetic Disparities Between African Americans and Causasians Utilizing Gene Expression Profiles (GEP) Of Purified Plasma Cells (PC) and Whole Bone Marrow Biopsies (BMBx)

Final Results Of Phase II Study Of Pomalidomide (Pom) In GEP-Defined High Risk Relapsed and Refractory Multiple Myeloma (RRMM)

Impact Of Elotuzumab Therapy On Circulating and Ex Vivo Activated/Expanded Autologous Natural Killer (Auto-ENK) Cell Activity

Role Of Cytogenetic Abnormalities At Baseline and During 5-Year Follow-Up In Multiple Myeloma Patients Treated On The Total Therapy 3 Protocol

Total Therapy (TT) Studies For Gene Expression Profiling (GEP)-Defined High-Risk Multiple Myeloma

Secondary Myelodysplasia-Associated Metaphase Cytogenetic Abnormalities in Newly Diagnosed Multiple Myeloma Treated On Total Therapies 2 & 3– Influence of Cumulative Dosing of Maintenance Drugs

Identifying the Outliers Among Gene Expression Profiling (GEP)-Defined Low-Risk Myeloma Patients Treated with Total Therapy 2 and 3 (TT2, TT3)

Abnormal Hevylite Assay Ratio As a Prognostic Marker for Survival in Newly Diagnosed Multiple Myeloma Patients Treated On Total Therapy 3

Phase II Study of Pomalidomide (Pom) in Genomically Defined High Risk Relapsed and Refractory Multiple Myeloma (RRMM)

18-FDG PET Focal Lesion and Avidity Suppression As Early As Day-7 Post-Induction Chemotherapy Predicts for Superior Outcome in Newly Diagnosed Multiple Myeloma Patients Treated with Total Therapy 3 Trials.

Total Therapy 6: Initial Results of Dose-Dense Strategy for Previously Treated Multiple Myeloma

Pomalidomide (Pom) in Relapsed and Refractory Multiple Myeloma (RRMM) - theUARK Compassionate Use Protocol,

Second Malignancies in Total Therapy 3 Trials for Newly Diagnosed Multiple Myeloma: Influence of Lenalidomide Versus Thalidomide in Maintenance Phases

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only